German drug maker Boehringer-Ingelheim and Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd. declared strategic cooperative agreement to build up the first Chinese biopharmaceutical base using mammal cell culture ...
Tags: Health, Medicine, Biopharmaceutical Base
GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for €250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the ...
Tags: Glaxosmithkline, Vaccines Business
Aurobindo Pharma has gained final FDA approval for its generic Nevirapine tablets and oral suspension used for treating human immunodeficiency virus (HIV). The FDA approved Nevirapine tablets of 200mg strength and Nevirapine oral ...
Tags: Aurobindo Pharma, FDA, Nevirapine, HIV drug
Spanish firm STAT-Diagnostica said it will invest $17m, arranged through Series B financing round, for completing the development of its Near Patient Testing diagnostic system. Using the proceeds, the company also plans to clinically ...
Boehringer Ingelheim and Eli Lilly and Company have announced the submission of new drug application (NDA) to FDA for an investigational type 2 diabetes mellitus (T2D) treatment, empagliflozin. Empagliflozin belongs to sodium glucose ...
Tags: diabetes therapy, drug application, drug
Boehringer Ingelheim has entered into a collaboration agreement with ChemAxon, a provider of cheminformatics software platforms. Under the agreement, Boehringer will implement ChemAxon's chemistry software platform for use in multiple ...
Tags: Boehringer Ingelheim, ChemAxon, cheminformatics software platforms
Eli Lilly and Company has reassumed the worldwide development and commercialization rights for novel basal insulin analog giving a scope to diabetes alliance signed with Boehringer concerning LY2605541. Lilly also considers initiating ...
Tags: Eli Lilly, commercialization rights, Boehringer, company news
Xylem Inc. announced the appointment of Nicholas R. Colisto as Senior Vice President and Chief Information Officer (CIO), effective December 19, 2012. He will report directly to Gretchen McClain, President and Chief Executive Officer of ...
Tags: Xylem Inc, information technology, Colisto, company news
US-based Boehringer Ingelheim Pharmaceuticals has announced the recall of a single manufacturing lot of Pradaxa (dabigatran etexilate mesylate) capsules in the US and Puerto Rico over packaging issue. The recall of Pradaxa, 75mg 60 US, ...
Tags: Packaging, packaging defect, Pharmaceuticals
Mylan Pharmaceuticals has gained final FDA approval for its abbreviated new drug application (ANDA) for Nevirapine Tablets USP, 200mg and initiated the shipment of the product. The generic version of Boehringer Ingelheim's Viramune is ...
Tags: Mylan pharmaceuticals, ANDA, ARV
Boehringer Ingelheim India and Eli Lilly India is set to launch Linagliptin (brand name trajenta) 5mg film-coated tablets, for Type 2 diabetes in adults, in India. Linagliptin, which is approved in the US, the European Union, Japan and ...
Tags: Diabetes Drug, product of Boehringer, diabetes epidemic
Ten biopharmaceutical companies, Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi have established a non-profit organization ...
Tags: biopharmaceutical companies, non-profit organization, new medicines
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. ...
Tags: FDA, sNDA, pharmaceutical product, clinical development
Boehringer Ingelheim and Funxional Therapeutics have signed an agreement under which Boehringer will acquire the global rights to Funxional's FX125L compound and somatotaxin program. Boehringer is responsible for all further research, ...
Boehringer Ingelheim and Eli Lilly and Company have received European Commission marketing authorization for Jentadueto (linagliptin/metformin hydrochloride) tablets. Jentadueto is a new, single-tablet treatment option, taken twice daily, ...
Tags: marketing authorization, Jentadueto tablets, glycemic control